2 completed, 1 available, 1 unknown. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow ansuvimab: new trials by email Literature Review of ansuvimab trials Research Report on ansuvimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylaxis Vaccine Antibodies Ebola ansuvimab, Ervebo - Ebola Virus Disease | Phase 2 | Unknown | ANRS, Emerging Infectious Diseases | 250 | 2021-10-17 | 2021-10-15 |
| Investigational Therapeutics for the Treatment of People With Ebola Virus Disease ZMapp, Remdesivir, MAb114 - Ebola Virus | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 681 | 2018-11-21 | 2021-09-08 |
| Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults VRC-EBOMAB092-00-AB (MAb114) - Healthy Adult Immune Responses to Vaccine | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 19 | 2018-05-16 | 2020-10-26 |
| Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP Ansuvimab - Ebola Virus Disease | Available | Ridgeback Biotherapeutics, LP | 2024-12-17 |
Hemorrhagic Fever, Ebola (3) · Hemorrhagic Fevers, Viral (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · ANRS, Emerging Infectious Diseases (1) · Ridgeback Biotherapeutics, LP (1)
United States (2) · Democratic Republic of the Congo (1) · Guinea (1)
Martin R Gaudinski, M.D. (1) · Richard T Davey, M.D. (1)